GeneDx Holdings Corp. (WGS) saw its stock price plummet 5.09% during intraday trading on Tuesday, reflecting significant selling pressure.
The sharp decline follows a series of analyst price target reductions for the company. According to research reports, BTIG lowered its target to $170 from $200, Jefferies cut its target to $150 from $180, Piper Sandler reduced its target to $130 from $160, and TD Cowen decreased its target to $135 from $165.
These coordinated downward revisions by multiple analysts suggest a reassessment of the company's near-term financial prospects, contributing to the negative investor sentiment and the stock's downward movement in the session.
Comments